CEO confirms GLP-1 users driving preventive and corrective aesthetics demand—practices should prepare for sustained volume and case-mix shifts.
Galderma's CEO confirmed that the surge in GLP-1 weight-loss drug adoption is directly boosting the company's aesthetics sales by approximately 25%, a material contribution to the company's record H1 2026 performance. The driver is twofold: GLP-1 users seeking preventive injectables to mitigate "Ozempic face" (volume loss, skin laxity) and corrective procedures post-weight loss (skin tightening, filler for restored contour).
This is not speculative. Galderma's data shows measurable uptick in Dysport, Radiesse, and Sculptra volume among practices serving GLP-1-using patient cohorts. The effect is strongest in urban, higher-income markets where GLP-1 penetration is highest.
Galderma CEO: GLP-1 weight-loss drugs are driving 25% of aesthetics sales growth—preventive and corrective demand both rising.
For practices, the implication is clear: GLP-1 adoption is reshaping case mix and patient acquisition. Practices in markets with high GLP-1 penetration should expect sustained demand for preventive toxin, volumizing fillers, and biostimulators. Marketing messaging around "GLP-1 support" and skin quality maintenance is becoming table stakes. Expect this tailwind to persist as GLP-1 adoption continues to climb.
Source: original report ↗
Frequently asked questions
How much are GLP-1 drugs boosting medspa revenue?
Galderma reported a 25% sales lift in aesthetics directly attributable to GLP-1 users. The demand comes from both preventive treatments (Dysport, Radiesse, Sculptra) to address volume loss and skin laxity, and corrective procedures post-weight loss for skin tightening and contour restoration.
What aesthetic procedures are GLP-1 patients requesting?
GLP-1 users are driving demand for preventive injectables like Dysport to combat 'Ozempic face,' volumizing fillers like Radiesse, and biostimulators like Sculptra. Post-weight loss, they're also seeking skin tightening and filler for restored facial contour.
Which markets are seeing the biggest GLP-1 aesthetics boom?
Urban, higher-income markets show the strongest uptick in GLP-1-driven aesthetics demand, correlating directly with higher GLP-1 penetration rates in those regions. Practices in these areas should expect sustained volume increases for preventive and corrective procedures.
How should medspa practices market to GLP-1 patients?
Marketing messaging around 'GLP-1 support' and skin quality maintenance is becoming essential for practices serving these patients. Positioning preventive toxin, volumizing fillers, and biostimulators as solutions for maintaining facial volume and skin elasticity during weight loss is now table stakes.
Will GLP-1 demand for aesthetics continue to grow?
Yes—Galderma's data confirms this is not speculative, and the tailwind is expected to persist as GLP-1 adoption continues to climb. Practices should prepare for sustained case-mix shifts toward preventive and corrective aesthetics in high-penetration markets.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
